Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

Concomitant inhibition of multiple cancer-driving kinases is an established strategy to improve the durability of clinical responses to targeted therapies. The difficulty of discovering kinase inhibitors with an appropriate multi-target profile has, however, necessitated the application of combinati...

Full description

Bibliographic Details
Main Authors: Ciceri, Pietro, Müller, Susanne, O’Mahony, Alison, Fedorov, Oleg, Filippakopoulos, Panagis, Hunt, Jeremy P., Lasater, Elisabeth A., Pallares, Gabriel, Picaud, Sarah, Wells, Christopher, Martin, Sarah, Wodicka, Lisa M., Shah, Neil P., Treiber, Daniel K., Knapp, Stefan
Format: Online
Language:English
Published: 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998711/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998711/

Similar Items